ProBioGen Celebrates "A New Dawn in Biotechnology"
Symposium Honors Chief Scientific Officer, Dr. Volker Sandig Berlin, Germany – September 30, 2022 The biotechnology firm ProBioGen held the symposium "A New Dawn in Biotechnology:..
ProBioGen Receives Employer of the Future and Top Service Awards
Biopharma Company Recognized at DIGITAL X 2022 Berlin, Germany – September 13, 2022 Today, the Berlin-based biopharmaceutical company ProBioGen received the Employer of the Future..
ProBioGen and City of Hope Announce Commercial License Agreement to Use AGE1.CR.pIX® Vaccine Manufacturing Platform for Cytomegalovirus (CMV) Vaccine
Berlin, Germany and Los Angeles, USA, September 7, 2022 ProBioGen and City of Hope, one of the largest cancer research and treatment organizations in the United States, announced..
ProBioGen Executes a Master Service Agreement with NextPoint Therapeutics and Starts an Integrated Project from Cell Line Development to GMP Manufacturing
Berlin, Germany and Cambridge, MA, USA, August 17, 2022 ProBioGen is delighted to close a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of..
ProBioGen Teams Up with Granite Bio for Cell Line Development and GMP Manufacturing Services
Berlin, Germany, July 12, 2022 Granite Bio, a Swiss biotech company built through Versant Venture's discovery engine Ridgeline Discovery, and ProBioGen announced the closure of a..
ValenzaBio Engages ProBioGen For a Second Service Project
Berlin, Germany and Bethesda, MD, USA, June 14, 2022 ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement. The new project is a..
ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®
Berlin, Germany and Bethesda, MD, USA, June 14, 2022 ProBioGen and ValenzaBio jointly announce today that they have entered into a second service agreement. The new project is a..
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
